glp-1 obesity drug news today october 23 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Agonists: Using Semaglutide, Tirzepatide,
Description
[PubMed] [Google Scholar] 47.Heinrich G., Gros P., Habener J.F
Kaur P, Mahendru S, Mithal A
Based on the PIONEER programme, oral semaglutide has been licensed for people with T2D and the 14 mg dose, leads to HbA1c improvement up to 1.4% and WL up to 4.4 kg [20]
10.1111/dom.12802 Summary Keywords type 2 diabetes, DPP-4 inhibitors, oral antidiabetic, incretin-based therapy, gliptin, combination therapy Citation Gallwitz B (2019) Clinical Use of DPP-4 Inhibitors
Requires urgent reperfusion therapy (PCI or thrombolysis)
doi: 10.1073/pnas.0706890104
